Intrabodies as antiviral agents

Current Topics in Microbiology and Immunology

Volumn 260, Issue , 2001, Pages 247-270

  Marasco, W A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5;

DRUG MECHANISM; EXPRESSION VECTOR; GENE THERAPY; GENETIC CODE; GENETIC TRANSDUCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PHAGE DISPLAY; PHENOTYPE; PRIORITY JOURNAL; PROTEOLIPOSOME; REVIEW; VIRUS LOAD;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0034971762     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-662-05783-4_13     Document Type: Review

References (124)

1. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with 250μl CD4 T cells and undetectable plasma virus load
2. Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo
3. Genetic co-inactivation of macrophage- and T-tropic HIV-1 chemokine coreceptors CCR-5 and CXCR-4 by intrakines
4. Intracellular immunization
5. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro
6. Assembly of combinatorial antibody libraries on phage surfaces: The gene III site
7. Human auto antibody recognition of DNA
8. T lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years
9. HSV-TK gene transfer into donor lymphocytes for control of allogenic graft-versus-leukemia
10. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients
11. Diversity of HIV-1 Vpr interactions involves usage of the WXXF motif of host cell proteins
12. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation
13. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients
14. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals
15. Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments
16. The selection of intracellular antibodies
17. Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible of the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2)
18. Inactivation of HIV-1 chemokine co-receptor CXCR-4 by a novel intrakine strategy
19. Intracellular antibodies as a new class of therapeutic molecules for gene therapy
20. Combined intra and extra-cellular immunization against human immunodeficiency virus type 1 infection using as human anti-gp120 antibody
21. Intra and extra-cellular immunization against HIV-1 infection with lymphocytes transduced with an AAV vector expressing a human anti-gp120 antibody gene
22. The â-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates
23. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection
24. Making antibody fragments using phage display libraries
25. Resisting resistance: Maximizing the durability of antiretroviral therapy
26. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals
27. Acute HIV syndrome after discontinuation of antiretroviral therapy in a patient treated before seroconversion
28. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus
29. Identification of a major co-receptor for primary isolates of HIV-1
30. Adaptation to promiscuous usage of chemokine receptors is not a prerequisite for human immunodeficiency virus Type 1 disease progression
31. The CCR5 receptor acts as an alloantigen in CCR5Ä32 homozygous individuals: Identification of chemokine and HIV-1 blocking human antibodies
32. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5
33. Potent inhibition of human immunodeficiency virus type 1 replication by an intracellular anti-Rev single chain antibody
34. Molecular and virological effects of intracellular anti-rev single-chain variable fragments on the expression of various human immunodeficiency virus-1 strains
35. Evaluation of lymph node virus burden in human immunodeficiency virus-infected patients receiving Efavirenz-based protease inhibitor-sparing highly active antiretroviral therapy
36. Immune-based therapies in HIV infection: Recent developments
37. Acquired immunodeficiency syndrome: Epidemiologic, clinical, immunologic, therapeutic considerations
38. A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5
39. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry
40. Differential tropism and chemokine receptor expression of human immunodeficiency virus type 1 in neonatal monocytes, monocyte-derived macrophages, and placental macrophages
41. + cells transduced with retroviral vectors containing an intracytoplasmatically truncated version of the human low-affinity nerve growth factor receptor (ÄLNGFR) gene
42. HIV-1 entry cofactor functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor
43. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
44. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
45. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS
46. Inhibition of murine leukaemia virus retrotranscription by the intracellular expression of a phage-derived anti-reverse transcriptase antibody fragment
47. The role of mononuclear phagocytes in HTLV-III/LAV infection
48. Gene therapy for infectious diseases: The AIDS model
49. Functions of the proteasome: The Lysis at the end of the tunnel
50. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: Evidence of a new acquired cellular immunodeficiency
51. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy
52. Multi-subunit proteins on the surface of filamentous phage: Methodologies for displaying antibody (Fab) heavy and light chains
53. Intracellular interference of tick-borne flavivirus infection by using a single-chain antibody fragment delivered by recombinant Sindbis virus
54. Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency type 1
55. The envelope glycoprotein ectodomains determine the efficiency of CD4+ T-lymphocyte depletion in simian-human immunodeficiency virus-infected macaques
56. Inhibition of replication of HIV-1 at both early and late stages of the viral life cycle by single-chain antibody against viral integrase
57. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV
58. A novel Vpr peptide interactor fused to integrase (IN) restores integration activity to IN-defective HIV-1 virions
59. Single amino acid change in tat determines the different rates of replication of two sequential HIV-1 isolates
60. Induction of inhibitory antibodies to the CCR5 chemokine receptor and their complementary role in preventing SIV infection in macaques
61. Inhibition of early and late events of the HIV-1 replication cycle by cytoplasmic Fab intrabodies against the matrix protein, p17
62. Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase
63. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection
64. CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 in vitro
65. Chemokines - Chemotactic cytokines that mediate inflammation
66. Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro
67. Design, intracellular expression and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody
68. Intracellular antibodies (intrabodies) as research reagents and therapeutic molecules for gene therapy
69. Intrabodies: Turning the humoral immune system outside in for intracellular immunization
70. Human anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS
71. Antiviral activity of an intracellularly expressed single-chain antibody fragment directed against the murine leukemia virus capsid protein
72. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses
73. By-passing immunization, human antibodies from V-gene libraries displayed on phage
74. Expression of an antibody fragment at high levels in the bacterial cytoplasm
75. A tumor specific single chain antibody dependent gene expression system
76. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations
77. Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies
78. Inhibition of human imunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-êB antagonists
79. Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4± mononuclear cells expressing murine and humanized anti-HIV-1 tat sFv intrabodies
80. Use of retroviral vectors for gene transfer and expression
81. Enhanced expression, native purification, characterization of CCR5, a principal HIV-1 coreceptor
82. Paramagnetic proteoliposomes containing a pure, native and oriented seven-transmembrane segment protein CCR5
83. Coreceptors: Implications for HIV pathogenesis and therapy
84. Genealogy of the CCR5 locus and chemokine system gene variants associated with altered rates of HIV-1 disease progression
85. Recombinant human immunodeficiency virus Type 1 genomes with tat unconstrained by overlapping reading frames reveal residues in Tat important for replication in tissue culture
86. Intrabody construction and expression. II. A synthetic catalytic Fv fragment
87. Production of uninfectious human immunodeficiency virus Type 1 containing viral protein R fused to a single-chain antibody against viral integrase
88. Packageable antiviral therapeutics against human immunodeficiency virus type 1: Virion-targeted virus inactivation by incorporation of a single-chain antibody against viral integrase into progeny virions
89. Immunotherapy of a viral disease by in vivo production of therapeutic monoclonal antibodies
90. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time
91. A randomized trial of three maintenance regimens given after three months of induction therapy with Zidovudine, Lamivudine, and Indinavir in previously untreated HIV-1-infected patients
92. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophage tropic isolates of HIV-1
93. High affinity, thyroid-specific human auto antibodies displayed on the surface of filamentous phage use V genes similar to other auto antibodies
94. + T-cells from HIV-infected individuals which express an intracellular antibody against HIV-1 gp 120 or tat
95. ± cells transduced with an intracellular antibody directed against HIV-1 tat
96. Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals
97. An env gene derived from a primary human immunodeficiency virus type 1 isolate confers high in vivo replicative capacity to a chimeric simian/human immunodeficiency virus in rhesus monkeys
98. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys
99. + T cell surface CCR5 density as a determining factor of virus load in person infected with human immunodeficiency virus type 1
100. Intrabody-mediated knockout of the high-affinity IL-2 receptor in primary human T cells using a bicistronic lentivirus vector
101. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients
102. A new foreign policy: MHC class I molecules monitor the outside world
103. High-efficiency retroviral vector mediated gene transfer into human peripheral blood CD4+ T lymphocytes
104. CCR5 has an expanded ligand-binding repertoire and is the primary receptor used by MCP-2 on activated T cells
105. Immunological studies of homosexual men with immunodeficiency and Kaposi's sarcoma
106. Targeting HIV-1 reverse transcriptase by intracellular expression of single chain variable fragments to inhibit early stages of the viral life cycle
107. Efficient construction of a large nonimmune phage antibody library: The production of high-affinity human single-chain antibodies to protein antigens
108. Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of Zidovudine, Lamivudine, and Ritonavir therapy
109. Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion
110. Prolonged asymptomatic HIV-1 infection
111. Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukeia: Clinical follow-up and improved new vectors
112. Selection of antibodies for intracellular function using a two-hybrid in vivo system
113. Viral dynamics in human immunodeficiency virus type 1 infection
114. Expression of a protective gene prolongs survival of T cells in human immunodeficiency virus-infected patients
115. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
116. Correlation between in vitro stability and in vivo performance of anti-GCN4 intrabodies as cytoplasmic inhibitors
117. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro
118. Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection
119. Human combinatorial antibody libraries to hepatitis B surface antigen
120. Cells transfected with a non-neutralizing antibody gene are resistant to HIV infection: Targeting the endoplasmic reticulum and trans-Golgi network
121. Immune reaction against the HIV-1 coreceptor CCR5
122. Intracellular expression of a cloned antibody fragment interferes with hepatitis B virus surface antigen secretion